Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

69P - Use of bevacizumab for patients with FIGO stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: A German cancer registry study

Date

20 Jun 2024

Session

Poster Display

Presenters

Andre Pfob

Citation

Annals of Oncology (2024) 9 (suppl_5): 1-19. 10.1016/esmoop/esmoop103501

Authors

A. Pfob1, I. Surovtsova2, D. Kokh3, O. Zivanovic1, G. Sauer4, P. Morakis3

Author affiliations

  • 1 University Hospital Heidelberg, Heidelberg/DE
  • 2 Krebsregister Baden-Württemberg, Germany, 70191 - Stuttgart/DE
  • 3 Krebsregister Baden-Württemberg, Germany, Stuttgart/DE
  • 4 Robert Bosch Hospital, Stuttgart/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 69P

Background

We aimed to evaluate the use of bevacizumab for patients with FIGO stage IIIB to IV advanced epithelial ovarian cancer (EOC) undergoing primary debulking surgery (PDS) in the primary disease setting using real-world data from a German cancer registry.

Methods

We identified patients with the initial diagnosis of FIGO stage IIIB to IV EOC, reported between 2009 and 2022 from the clinical cancer registry of Baden-Wuerttemberg, Germany. We excluded patients with recurrent disease, neoadjuvant chemotherapy, inoperable disease, or with insufficient information on systemic treatment or follow-up. The influence of Bevacizumab in addition to Carboplatin and Paclitaxel (Cb+T+Bev vs. Cb+T) on progression-free survival (PFS) and overall survival (OS) was assessed using Kaplan- Meier statistics and multivariate Cox regression models, adjusted for age, grading, stage, tumor histology, use of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, and PDS outcome (macroscopic complete gross resection, residual disease ≤1cm and >1cm).

Results

A total of 835 patients with a median follow-up of 25.1 months were identified: 542 patients (64.9%) had FIGO stage IIIB/C disease, 293 (35.1%) had FIGO stage IV disease. Post-operative residual disease was complete gross resection in 468 (56.0%), ≤1cm in 181 (21.7%), and >1cm in 186 (22.3%). Median age was 63.8 years (SD 11.1). Use of Cb+T+Bev was 40.1% (335/835) overall, 43.8% (205/468) for patients with complete gross resection, 38.7% (70/181) for patients with ≤1cm residual disease, and 32.3% (60/186) for patients with >1cm residual disease. Cb+T+Bev was not associated with improved OS (HR 0.88, 95% CI 0.73-1.07, P=0.216) or PFS (HR 0.95, 95% CI 0.79-1.10, P=0.610). Also in the subgroup of patients with >1cm residual disease, Cb+T+Bev was not associated with improved OS (HR 0.90, 95% CI 0.61-1.31, P=0.565) or PFS (HR 0.86, 95% CI 0.56-1.32, P=0.483).

Conclusions

This data suggests that bevacizumab is often used for patients with primary FIGO stage IIIB to IV EOC undergoing PDS although it does not provide an OS or PFS benefit.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.